1. Home
  2. FIHL vs EVO Comparison

FIHL vs EVO Comparison

Compare FIHL & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fidelis Insurance Holdings Limited

FIHL

Fidelis Insurance Holdings Limited

HOLD

Current Price

$20.71

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

N/A

Current Price

$2.80

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FIHL
EVO
Founded
2014
1993
Country
Bermuda
Germany
Employees
N/A
4553
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.1B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
FIHL
EVO
Price
$20.71
$2.80
Analyst Decision
Hold
Strong Buy
Analyst Count
7
1
Target Price
$22.79
$7.00
AVG Volume (30 Days)
345.1K
40.1K
Earning Date
05-13-2026
04-08-2026
Dividend Yield
2.87%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.94
$1.37
Revenue Next Year
$7.04
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.80
$2.31
52 Week High
$21.50
$4.42

Technical Indicators

Market Signals
Indicator
FIHL
EVO
Relative Strength Index (RSI) 53.28 43.13
Support Level $17.93 $2.63
Resistance Level $21.45 $3.82
Average True Range (ATR) 0.49 0.07
MACD -0.07 -0.00
Stochastic Oscillator 30.70 21.62

Price Performance

Historical Comparison
FIHL
EVO

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: